| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
- |
| Employees |
51 |
| Revenues (TTM) (Millions $) |
10 |
| Net Income (TTM) (Millions $) |
-61 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Immutep Limited is a biotechnology company based in Sydney, Australia. The company focuses on developing immunotherapeutic products for the treatment of cancer and autoimmune diseases. Immutep's main product candidate is called eftilagimod alpha (efti), which is designed to stimulate the immune system to fight cancer cells.
Efti is being investigated in various clinical trials for the treatment of different types of cancer, including breast, lung, and renal cell cancers. The company also collaborates with pharmaceutical companies to develop combination therapies using efti and other immune checkpoint inhibitors.
Immutep is known for its expertise in the field of antigen-presenting cell biology and its ability to modulate the immune response. The company's research and development efforts are aimed at improving the efficacy of immunotherapies and advancing the understanding of immune system interactions.
In addition to its clinical development programs, Immutep is also actively engaged in strategic collaborations and licensing agreements to further advance its product pipeline. The company has a global presence and collaborates with academic institutions, healthcare organizations, and industry leaders to accelerate the development of novel immunotherapies.
Company Address: Level 32, Australia Square Sydney 2000
Company Phone Number: 8315 7003 Stock Exchange / Ticker: NASDAQ IMMP
|
48.73 %